Table 6.
Description of recommended systematic review endpoints.
| Number of studies | Endpoint | ||
|---|---|---|---|
| Estrogenic activity | Androgenic activity | Offspring growth | |
| Human | 0 | 0 | 1 |
| Rodent | 1 | 2 | 2 |
| Fish | 6 | 5 | 3 |
| Invertebrates | 2 | 0 | 1 |
| In vitro | 5 | 7 | 2∗∗ |
|
| |||
| Total∗ | 14 | 14 | 9 |
|
| |||
| Dose range | |||
| Human (detected) | NA | NA | 0.13 µg/L (cord blood plasma); 3.44 µg/g creatinine (urine) |
| Rodent | 0.2–0.5% w/w | 0.25% w/w | 100 mM, 0.2–0.5% w/w TCC |
| Aquatic | 0.045–14.0 µg/L | 0.55–10 µg/L | 0.1–10000 µg/L |
| In vitro | 1 × 10−9–1 × 10−3 M | 1 × 10−9–2 × 10-3 M | 3 × 10−6–3 × 10−2 M |
∗ In vitro/in vivo assessments counted separately, even if included in the same publication. ∗∗Thyroid activity.